

-144-


CLAIMS

What is claimed is:

1. A Compound of the structural formula I:

5

Formula I



- (v) R1 is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₃-C₆ cycloalkyl, aryl-C_{0.4}-alkyl, heteroaryl-C_{0.4}-alkyl, aminoC₁-C₄alkyl, C₃-C₆ cycloalkylaryl-C_{0.2}-alkyl, arylheteroC₁-C₈alkyl, -CHC(O)C₁-C₄ alkoxy, C_{0.4}-alkyl-C(O)heteroC₁-C₈alkyl, and -CH₂-C(O)-R15-R16; and which C₁-C₈ alkyl, C₃-C₆ cycloalkyl, aryl-C_{0.4}-alkyl, heteroaryl-C_{0.4}-alkyl, aminoC₁-C₄alkyl, C₃-C₆ cycloalkylaryl-C_{0.2}-alkyl, arylheteroC₁-C₈alkyl, -CHC(O)C₁-C₄ alkoxy, C_{0.4}-alkyl-C(O)heteroC₁-C₈alkyl and -CH₂-C(O)-R15-R16 are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R1'; and wherein R15 is O or NH and R16 is C₁-C₂ alkyl or benzyl, which C₁-C₂ alkyl or benzyl are each unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R16';
- (w) R1' and R2' are each independently a group consisting of C₁-C₅ alkyl, C₃-C₆ cycloalkyl, C₁-C₅ alkoxy, arylC₀-C₂alkoxy, haloC₁-C₃alkyl, halo, aryl, -C(O)C₁-C₅alkyl, -C(O)-aryl, haloC₁-C₅alkyloxy, arylC₁-C₅alkyl, and biarylC₁-C₅alkyl; and which -C(O)-aryl is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of halo, C₁-C₅ alkyl, haloC₁-C₅ alkyl, C₁-C₅ alkoxy, and -C(O)C₁-C₅alkyl; and which C₁-C₅ alkyl, arylC₁-C₅alkyl, biarylC₁-C₅alkyl, and aryl are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of halo, C₁-C₈alkyl, aryl, haloC₁-C₅ alkyl, trihaloC₁-C₃alkyl, C₁-C₅alkoxy, and arylC₁-C₅alkyl; and which aryl is unsubstituted or substituted with from one to three substituents each

-145-

independently selected from the group consisting of halo, C₁-C₈alkyl, aryl, haloC₁-C₅alkyl, trihaloC₁-C₃alkyl, C₁-C₅alkoxy, and arylC₁-C₅alkyl;

(x) R₂ is selected from the group consisting of C₁-C₈ alkyl, C₃-C₆ cycloalkyl, aryl-C₀₋₄-alkyl, heteroaryl-C₀₋₄-alkyl, hetoC₁-C₆cycloalkylaryl, hetoC₁-

5 C₆cycloalkylarylC₁-C₄alkyl, aminonoC₁-C₄alkyl, C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl, arylheteroC₁-C₈alkyl, C₀₋₄-alkyl-C(O)heteroC₁-C₈alkyl, -CH(C(O)OCH₃)benzyl, and -CH₂-C(O)-R_{15''}-R_{16''}, and which C₁-C₈ alkyl, C₃-C₆ cycloalkyl, aryl-C₀₋₄-alkyl, hetoC₁-C₆cycloalkylaryl, hetoC₁-C₆cycloalkylarylC₁-C₄alkyl, heteroaryl-C₀₋₄-alkyl, aminoC₁-C₄alkyl, C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl, arylheteroC₁-C₈alkyl, C₀₋₄-alkyl-
10 C(O)heteroC₁-C₈alkyl, and -CH₂-C(O)-R_{15''}-R_{16''} are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R₂';

(y) R_{15''} is O or NH;

(z) R_{16''} is C₁-C₂ alkyl or benzyl which C₁-C₂ alkyl and benzyl are each
15 unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R₁₆';

(aa) R₁ and R₂ together may form a heterocyclic ring which heterocyclic ring is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R₁' and which heterocyclic ring is optionally fused
20 with an aryl;

(bb) E is selected from the group consisting of C(R₃)(R₄)A, (CH₂)_n COOR₁₃, aryl-C₀₋₄-alkyl, thio-C₁-C₄-alkyl, thioaryl, arylC₁-C₄alkoxy, C₁-C₄alkoxy C₁-C₄alkyl, aminoaryl, and amino C₁-C₄alkyl; and which (CH₂)_n COOR₁₃, aryl-C₀₋₄-alkyl, thio- C₁-C₄-alkyl, thioaryl, C₁-C₄alkoxyaryl, C₁-C₄alkoxyC₁-C₄alkyl, aminoaryl, and aminoC₁-
25 4alkyl are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of E';

(cc) R₇' and R_{7''} are each independently selected from the group consisting of C₁-C₄ alkyl and C₁-C₄ haloalkyl;

(dd) n and m are each independently selected from the group consisting of 0, 1,
30 2 and 3;

-146-

(ee) A is selected from the group consisting of $(\text{CH}_2)_m \text{COOR}_{14}$, C_1 - C_3 alkylnitrile, carboxamide, sulfonamide, acylsulfonamide and tetrazole, and which sulfonamide, acylsulfonamide and tetrazole are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of A' ;

(ff) A' is a group consisting of C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, heteroaryl, and aryl, and wherein heteroaryl and aryl are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of halo, C_1 - C_5 alkyl, C_1 - C_5 haloalkyl, C_1 - C_5 alkoxy, and $-\text{C}(\text{O}) \text{C}_1$ - C_5 alkyl;

(gg) R_3 is selected from the group consisting of H, C_1 - C_5 alkyl, C_1 - C_5 alkenyl, and C_1 - C_6 alkoxy;

(hh) R_4 is selected from the group consisting of H, halo, C_1 - C_5 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, aryl C_0 - C_4 alkyl, and C_0 - C_4 alkoxyaryl, and which C_1 - C_5 alkyl, C_1 - C_5 alkoxy, C_3 - C_6 cycloalkyl, aryl C_0 - C_4 alkyl, and C_0 - C_4 alkoxyaryl are each independently unsubstituted or each independently substituted with from one to four substituents each independently selected from R_4' ; or R_3 and R_4 are combined to form a C_3 - C_6 cycloalkyl;

(ii) R_5 and R_6 are each independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl, aryl- C_0 - C_4 -alkyl, heteroaryl- C_0 - C_4 -alkyl, C_3 - C_6 cycloalkylaryl- C_0 - C_2 -alkyl, C_3 - C_6 cycloalkyl- C_0 - C_2 -alkyl, and $-\text{CH}_2-\text{C}(\text{O})-\text{R}_{17}-\text{R}_{18}$, and which C_1 - C_8 alkyl, aryl- C_0 - C_4 -alkyl, heteroaryl- C_0 - C_4 -alkyl, C_3 - C_6 cycloalkylaryl- C_0 - C_2 -alkyl, C_3 - C_6 cycloalkyl- C_0 - C_2 -alkyl, and $-\text{CH}_2-\text{C}(\text{O})-\text{R}_{17}-\text{R}_{18}$ are each independently unsubstituted or substituted with from one to four substituents each independently selected from the group consisting of R_5' ;

(jj) E' , R_4' , R_5' , and R_{13}'' are each independently a group consisting of C_1 - C_5 alkyl, C_1 - C_5 alkoxy, C_1 - C_5 haloalkyl, C_1 - C_5 haloalkoxy, nitro, cyano, CHO, hydroxy, C_1 - C_4 alkanolic acid, phenyl, aryloxy, $\text{SO}_2\text{R}_7'$, SR_7'' , aryl- C_0 - C_2 alkoxy, C_1 - C_6 alkylcarboxamido, and COOH;

(kk) R_{16}' is a group consisting of halo, C_1 - C_8 alkyl, aryl, haloalkyl, trihalo- C_1 - C_3 alkyl, C_1 - C_5 alkoxy, and aryl- C_1 - C_5 alkyl;

-147-

(ll) R17 and R18 are each independently selected from C₁-C₈ alkyl, aryl-C₀₋₄-alkyl, heteroaryl-C₀₋₄-alkyl, C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl, and C₃-C₆ cycloalkyl-C₀₋₂-alkyl;

5 (mm) R13 and R14 are each independently selected from the group consisting of hydrogen, C₁-C₄alkyl, aryl, and arylmethyl, and which C₁-C₄alkyl are each independently unsubstituted or independently substituted with from one to three substituents each independently selected from the group consisting of R13' and which arylmethyl and aryl are each independently unsubstituted or independently substituted with from one to three substituents each independently selected from the group consisting
10 of R14';

(nn) R13' is a group consisting of C₁-C₅ alkyl, C₃-C₆ cycloalkyl, C₁-C₅ haloalkyl, C₁-C₅ alkoxy, aryloxy, halo, aryl, -C(O)C₁-C₅alkyl, -C(O)-aryl, haloC₁-C₅alkyloxy, aryl C₁-C₅ alkyl, and C₁-C₅ alkylbiaryl, and which -C(O)aryl, aryl, aryl C₁-C₅ alkyl, and C₁-C₅ alkylbiaryl are each independently unsubstituted or substituted with
15 from one to three substituents each independently selected from the group consisting of R13''; and


(oo) R14' is a group consisting of halo, C₁-C₈alkyl, C₁-C₅ haloalkyl, C₁-C₅ alkoxy, and arylC₀-C₄alkyl; or

(pp) a pharmaceutically acceptable salt thereof.

20

-148-


2. A compound as claimed by Claim 1 of the structural Formula II:



II

5 wherein R19 is selected from the group consisting of hydrogen, C1-C4alkyl, aryl, and arylmethyl, wherein the alkyl, aryl and arylmethyl are each unsubstituted or substituted with from one to three substituents each independently selected from R14'.

3. A compound as claimed by any one of Claims 1 to 2 that is of the
10 following structural formula III:



O

III

15 wherein R19 is selected from the group consisting of hydrogen, C1-C4alkyl, aryl, and arylmethyl, wherein the alkyl, aryl and arylmethyl are each unsubstituted or substituted with from one to three substituents each independently selected from R14'.

4. A compound as claimed by any one of Claims 1 to 3 wherein R1 is selected from the group consisting of hydrogen, C1-C4 alkyl, and arylC0-C4alkyl; R2 is selected from the group consisting of arylC0-C4alkyl, and heteroarylC0-C4alkyl.

- 20 5. A compound as claimed by any one of Claims 1 to 4 wherein R2 is selected from the group consisting of arylC0-C4alkyl, C1-C8 alkyl, heteroarylC0-C4alkyl, C3-C6 cycloalkyl, C0-C4alkyl-C(O)-heteroC1-C8 alkyl, arylheteroC1-C8alkyl, wherein each of said R2 is unsubstituted or substituted by one or two substituents each independently

-149-

selected from the group consisting of phenyl, halophenyl, phenoxy, halo, haloC₁-C₄ alkyl, C₁-C₄alkoxy, and C₃-C₆ cycloalkyl.

6. A compound as claimed by Claim 5 wherein R₂ is arylC₀-C₄alkyl wherein the aryl is phenyl or naphthyl, and the C₀-C₄alkyl is selected from the group consisting of methyl, ethyl and not present, that is C₀ alkyl.

7. A compound as claimed by Claim 5 wherein R₂ is heteroarylC₀-C₄alkyl, and said heteroarylC₀-C₄alkyl is unsubstituted or substituted with from one to three substituents each independently selected from R₂'; and wherein the heteroaryl is selected from the group consisting of pyridine, thiazole, benzothiazole, and thiadiazole; and the alkyl is selected from the group consisting of methyl, ethyl and not present, that is C₀ alkyl.

8. A compound as claimed by Claim 5 wherein R₂ is arylheteroC₁-C₈alkyl, wherein the arylheteroC₁-C₈alkyl is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R₂'; wherein the aryl group is phenyl, and the heteroatom is selected from the group consisting of nitrogen, sulfur and oxygen.

9. A compound as claimed by any one of Claims 1 to 8 wherein the R₂ group is substituted with one or two substituents each independently selected from the group consisting of methyl, ethyl, t-butyl, fluorine, chlorine, bromine, trifluoromethyl, methoxyl, ethoxyl, phenyl, and phenoxyl.


10. A compound as claimed by any one of Claim 1 to 3 wherein R₁ and R₂ together form a ring selected from the group consisting of piperidine, piperazine, and dihydroisoquinoline, wherein said piperidine, piperazine, and dihydroisoquinoline is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of C₁-C₄ alkyl, phenyl, halophenyl, trifluoromethylphenyl, methylphenyl, methoxyphenyl, acetylphenyl, benzyl, halobenzyl, benzoyl, halobenzoyl, trifluoromethylbenzoyl, methylbenzoyl, methoxybenzoyl, acetyl

-150-


benzoyl, biphenylmethylene, (phenyl)(halophenyl)methylene, and bihaolophenylmethylene.

11. A compound as claimed by Claim 10 wherein said piperidine and
5 piperazine is fused with a phenyl to form a bicyclic ring.

12. A compound as claimed by any one of Claims 1 to 9 wherein R2 is unsubstituted or substituted heteroarylC0-C4alkyl; wherein said heteroaryl is selected from the group consisting of:



13. A compound as claimed by any one of Claims 1 to 9 wherein R2 is unsubstituted or independently substituted with from one to three each independently
15 selected from R2', and wherein R1 is selected from the group consisting of:



-151-

14. A compound as claimed by any one of Claims 1 to 3, 9 or 13 wherein R₂ is -CH(C(O)OCH₃)benzyl.

15. A compound as claimed by any one of Claims 1 to 14 wherein R₆ is
5 selected from the group consisting of hydrogen, C₁-C₄ alkyl, and aryl-C₀₋₄-alkyl,
wherein the alkyl and arylalkyl are each independently substituted with from one to three
substituents each independently selected from the group consisting of R₅'.

16. A compound as claimed by any one of Claims 1 to 15 wherein R₅ is H or
10 methyl.

17. A compound as claimed by any one of Claims 1 to 14 or 16 wherein R₆ is
C₁-C₃ alkyl.

18. A compound as claimed by any one of Claims 1 to 14 or 16 to 17, wherein
15 R₆ is methyl.


19. A compound as claimed by any one of Claims 1 or 4 to 18 wherein E is
20 C(R₃)(R₄)A.

20. A compound as claimed by any one of Claims 1 or 4 to 18 wherein R₅ is
hydrogen or methyl, R₆ is C₁-C₃ alkyl, and E is C(R₃)(R₄)A, and R₃ is C₁-C₃alkoxy.

21. A compound as claimed by any one of Claims 1 or 4 to 19 wherein E is
25 C(R₃)(R₄)A and A is C(O)OR₂₆; R₂₆ is H or C₁-C₃alkyl.

-152-


22. A compound as claimed by any one of Claims 1, 4, 5, 10, or 15 to 20 that is of the structural formula IV:



IV

wherein R11 is selected from the group consisting of aryl, -C(O)aryl, haloC₁-C₅alkyloxy, C₁-C₅ alkylaryl, C₁-C₅ alkylbiaryl, aryloxy, and C1-C6 alkyl, wherein the aryl, -C(O)aryl, haloC₁-C₅alkyloxy, C₁-C₅ alkylaryl, C₁-C₅ alkylbiaryl, and C1-C6 alkyl are each independently unsubstituted or each independently substituted with from one to three substituents each independently selected from the group consisting of R1'.

23. A compound as claimed by any one of Claims 1 to 5, 10, or 15 to 20 that is of the structural formula V:




V

wherein R12 is selected from the group consisting of aryl, aryloxy, -C(O)aryl, haloC₁-C₅alkyloxy, C₁-C₅ alkylaryl, C₁-C₅ alkylbiaryl, and C1-C6 alkyl, wherein the aryl, -C(O)aryl, haloC₁-C₅alkyloxy, C₁-C₅ alkylaryl, C₁-C₅ alkylbiaryl, and C1-C6 alkyl are each independently unsubstituted or each independently substituted with from one to three substituents each independently selected from the group consisting of R1'.

-153-

24. A compound as claimed by any one of Claims 1 to 5, 10, or 15 to 20 that is




of the structural formula VI:

VI

- 5 wherein R12 is selected from the group consisting of aryl, aryloxy, -C(O)aryl, haloC₁-C₅alkyloxy, C₁-C₅ alkylaryl, C₁-C₅ alkylbiaryl, and C1-C6 alkyl, wherein the aryl, -C(O)aryl, haloC₁-C₅alkyloxy, C₁-C₅ alkylaryl, C₁-C₅ alkylbiaryl, and C1-C6 alkyl are each independently unsubstituted or each independently substituted with from one to three substituents each independently selected from the group consisting of R1'; R25 is
10 selected from the group consisting of C1-C4alkyl, halo, haloC1-C3alkyl, C1-C5 alkoxy, and phenyl.

25. A compound as claimed by any one of Claims 1, 4, 5, 10, or 13 to 18 that is of the structural formula VII:



O

VII

- 15 wherein wherein R12 is selected from the group consisting of aryl, aryloxy, -C(O)aryl, haloC₁-C₅alkyloxy, arylC₁-C₅ alkyl, C₁-C₅ alkylbiaryl, and C1-C6 alkyl, wherein the aryl, -C(O)aryl, aryloxy, haloC₁-C₅alkyloxy, C₁-C₅ alkylaryl, C₁-C₅ alkylbiaryl, and C1-C6
20 alkyl are each independently unsubstituted or each independently substituted with from one to three substituents each independently selected from the group consisting of R1'; R25 is selected from the group consisting of C1-C4alkyl, halo, haloC1-C3alkyl, C1-C5 alkoxy, and phenyl.

26. A compound as claimed by Claim 1 which is selected from the group consisting of:

(2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid; (2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid; (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S,1'R)-3-(4-{1'-[(biphenyl-3-ylmethyl)-carbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(3-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(3-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid; (2S,1'R)-3-(4-{1'-[2-(4-tert-butyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(4-fluoro-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid; (2S,1'R)-2-ethoxy-3-{4-[1'-(4-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S,1'R)-3-{4-[1'-(4-tert-butyl-benzylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid; (2S,1'R)-3-{4-[1'-(4-tert-butyl-phenylcarbamoyl)-ethoxy]-phenyl}-2-

-155-

ethoxy-propionic acid;(2S,1'R)-3-{4-[1'-(4-trans-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;

(2S)-3-{4-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;

5 (2S)-2-methoxy-3-(4-{1-methyl-1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

10 2-methoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-2-methoxy-3-{4-[1-methyl-1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid; (2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

15 (2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

20 (2S)-2-ethoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-2-ethoxy-3-{4-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-propionic acid;

25 (2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

30 (2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

-156-

(2S)-2-ethoxy-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;

(2S)-3-{3-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;

5 (2S)-3-{3-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;

(2S)-3-(3-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

10 (2S)-3-(3-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-2-methoxy-3-{4-[(1-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;

(2S)-3-(3-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

15 (2S)-3-(3-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

20 (2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-2-ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;

25 (2S)-2-ethoxy-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;

2-Ethoxy-3-{4-[1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

30 2-Ethoxy-3-{4-[1-(5-fluoro-3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(3-phenyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

-157-

2-Ethoxy-3-{4-[1-(4-phenoxy-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(3-trifluoromethyl-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

5 3-(4-{1-[2-(2,6-Dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

10 2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

3-(4-{Cyclohexyl-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-ethoxy-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-2-phenyl-ethoxy}-phenyl)-propionic acid; and

15 (2S,1'R)-2-ethoxy-3-{4-[1'-(2-thiophen-2-yl-ethylcarbamoyl)-ethoxy]-phenyl}-propionic acid; or pharmaceutically acceptable salts thereof.


27. A compound as claimed by Claim 1 wherein the compound is selected from the group consisting of

20 (2S,1'R)-3-{4-[1'-(4-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[(thiophen-2-ylmethyl)-carbamoyl]-ethoxy}-phenyl)-propionic acid;

25 (2S,1'R)-2-ethoxy-3-{4-[1'-(2-thiophen-2-yl-ethylcarbamoyl)-ethoxy]-phenyl}-propionic acid; or
pharmaceutically acceptable salts thereof.

28. A compound as claimed by Claim 1 wherein the compound is



; or a pharmaceutically acceptable salt thereof.

-158-

29. A compound as claimed by any one of Claims 1 through 28 which is the hemipiperazine salt.

30. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and at least one compound as claimed by any one of Claims 1-29 or a pharmaceutically acceptable salt thereof.

31. A method of modulating a peroxisome proliferator activated receptor, comprising the step of contacting the receptor with at least one compound as claimed by any one of Claims 1-29 or a pharmaceutically acceptable salt thereof.

32. A method of treating diabetes mellitus in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claims 1-29 or a pharmaceutically acceptable salt thereof.

33. A method of preventing diabetes mellitus in a mammal, comprising the step of administering to the mammal an effective amount of at least one compound of Claims 1-29 or a pharmaceutically acceptable salt thereof.

34. A method of treating Syndrome X in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claims 1-29 or a pharmaceutically acceptable salt thereof.

35. Use of a compound or pharmaceutically acceptable salt thereof as defined in any one of Claims 1 to 29, for the manufacture of a medicament for the treatment of a diabetes.

36. A compound or pharmaceutically acceptable salt thereof according to any one of Claims 1 through 29 for use as a medicine.

-159-

37. Use of a compound or pharmaceutically acceptable salt thereof as defined in any one of Claims 1 to 29 for the manufacture of a medicament for the treatment or prevention of diabetes mellitus in a mammal.

5 38. Use of a compound or pharmaceutically acceptable salt thereof as defined in any one of Claims 1 to 29 for the manufacture of a medicament for the treatment of Syndrome X in a mammal.

39. A compound as disclosed by any one of the examples herein.

10